The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially inWestern countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.

Ivabradine, heart failure and chronic kidney disease / L. Di Lullo, A. Bellasi, D. Russo, M. Cozzolino, C. Ronco, A. Santoboni, G. Barbera. - In: NEPHROLOGY@POINT OF CARE. - ISSN 2059-3007. - 1:1(2016 Jan), pp. e39-e43. [10.5301/poc.5000190]

Ivabradine, heart failure and chronic kidney disease

A. Bellasi
Secondo
;
M. Cozzolino;
2016-01

Abstract

The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially inWestern countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.
Beta-blockers; Heart failure; Ivabradine; Ventricular remodeling
Settore MED/14 - Nefrologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ivabradina NAPOC.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 200.21 kB
Formato Adobe PDF
200.21 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/357023
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
social impact